Determination of HER2 Gene Amplification in Breast Cancer using Dual-color Silver Enhanced in situ Hybridization (dc-SISH) and Comparison with Fluorescence ISH (FISH)

  • Unal, Betul (Department of Pathology, Antalya Research and Training Hospital) ;
  • Karaveli, Fatma Seyda (Department of Pathology, Akdeniz University Medical School) ;
  • Pestereli, Hadice Elif (Department of Pathology, Akdeniz University Medical School) ;
  • Erdogan, Gulgun (Department of Pathology, Akdeniz University Medical School)
  • Published : 2013.10.30


Background: The two basic methods that are currently accepted to identify the HER2 status are immunohistochemistry and flyorescence in situ hybridization (FISH). The aim of this study was to perform the dual-color silver in situ hybridization (dc-SISH) technique as an alternative to FISH. Materials and Methods: A total of 40 invasive breast carcinoma cases were assessed for HER2 gene amplification by FISH and dual-color SISH. Results: Significant correlation was found in the HER2 expression results obtained with the two approaches (p=0.001, p<0.05). The concordance rate was 92.3%. Conclusions: Foutine practical use of the dc-SISH method, which is much easier to apply, score, and evaluate, has many advantages. HER2 and CEN17 status can be evaluated simultaneously with the newly developed "Dual-Color Probe". All these specifications and the reliable results obtained support the widespread use of SISH technique in clinical practice.


Dual color SISH;breast cancer;Her2


  1. Coussens L, Yang-Feng TL, Liao YC, et al (1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science, 230, 1132-9.
  2. Arnould L, Roger P, Macgrogan G, et al (2012). Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH). Mod Pathol, 25, 675-82.
  3. Bilous M, Morey AL, Armes JE, et al (2012). Assessing HER2 amplification in breast cancer: findings from the Australian in situ hybridization program. Breast Cancer Res Treat, 134, 617-24.
  4. Carbone A, Botti G, Gloghini A, et al (2008). Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists. J Mol Diagn, 10, 527-36.
  5. Dekker TJ, Borg ST, Hooijer GK, et al (2012). Determining sensitivity and specifitcity of HER2 testing in breast cancer using a tissue micro-array approach. Breast Cancer Res, 14, 93.
  6. Lee Y, Ryu Y, Jeong H, et al (2012). Effectiveness of silver-enhanced in situ hybridization for evaluating HER2 gene status in invasive breast carcinoma: a comparative study. Arch Med Res, 43, 139-44.
  7. Dietel M, Ellis IO, Hofler H, et al (2007). Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists.Virchows Arch, 451, 19-25.
  8. Francis GD, Jones MA, Beadle GF, Stein SR (2009). Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. Diagn Mol Pathol, 18, 88-95.
  9. Gschwind A, Fischer OM, Ullrich A (2004). The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer, 4, 361-70.
  10. Paik S, Park C (2001). HER-2 and choice of adjuvant chemotherapy in breast cancer. Semin Oncol, 28, 332-5.
  11. Papouchado BG, Myles J, Lloyd RV, et al (2010). Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. Am J Surg Pathol, 34, 767-76.
  12. Park K, Han S, Kim JY, et al (2011). Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer. J Breast Cancer, 14, 276-82.
  13. Penault-Llorca F, Bilous M, Dowsett M, et al (2009). Emerging Technologies for assesing Her2 Amplification. Am J Clin Pathol, 132, 539-48.
  14. Thang VH, Tani E, Van TT, Krawiec K, Skoog L (2011). HER2 status in operable breast cancers from Vietnamese women:Analysis by immunohistochemistry (IHC) and automated silver enhanced in situ hybridization (SISH). Acta Oncol, 50, 360-6.
  15. Schiavon BN, Jasani B, de Brot L, et al (2012). Evaluation of reliability of FISH versus brightfield dual-probe in situ hybridization (BDISH) for frontline assessment of HER2 status in breast cancer samples in a community setting: influence of poor tissue preservation. Am J Surg Pathol, 36, 1489-96.
  16. Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82.
  17. Slamon DJ, Godolphin W, Jones LA, et al (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-12.
  18. Tvrdik D, Stanek L, Skalova H, et al (2012). Comparison of the IHC, FISH, SISH and qPCR methods for the molecular diagnosis of breast cancer. Mol Med Report, 6, 439-43.
  19. Ying JM, Guo L, Liu XY, Qiu T, Lu N (2010). Automated silver-enhanced in situ hybridization detection assay for human epidermal growth factor receptor 2 gene status determination in breast cancer. Zhonghua Yi Xue Za Zhi, 90, 1674-7.

Cited by

  1. hybridization: where are we now? vol.15, pp.3, 2015,
  2. Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment vol.468, pp.4, 2016,